Nontuberculous Mycobacterial Lung Disease: Real-World Application of New Guidelines and Treatment Advances

CME: 2.0

May 21, 2021
/ Print / Reprints /
| Share More
/ Text Size+

Target Audience

This activity was developed for pulmonologists, infectious disease specialists, and other healthcare professionals who care for patients with lung diseases.

Program Overview

Nontuberculosis mycobacterial lung disease (NTM-LD) is a frequently fatal lung disease that is now more common than tuberculosis in the United States. Treatment is generally very challenging due to lack of medications approved for first-line therapy, adverse events, drug-drug interactions, need for long-term dual and triple combination therapy, among other issues. This is a 2-part activity. Throughout the activity, the faculty share their experiences and provide pearls and pitfalls in overcoming the challenges in managing patients with NTM-LD.

Learning Objectives

Upon completion of this activity, participants should be better able to:

  • Describe key treatment concepts as described in the 2020 clinical practice guideline on nontuberculous mycobacterial lung disease (NTM-LD) jointly sponsored by American Thoracic Society, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, and Infectious Diseases Society of America
  • Summarize the clinical impact of the latest clinical data and therapeutic advances in NTM-LD
  • Develop patient-centered treatment strategies for NTM-LD that align with the latest evidence-based guideline recommendations and therapeutic advances
  • Collaborate with patients to better individualize treatment over the course of the disease

Post a comment to this article